RxDoctor Payments Data

Pen Lee, MD

Internal Medicine · Monterey Park, CANPI 1992807267

Payments from drug & device makers

$2,889in general payments, 2019–2025

Across 56 payments — averaging $51.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Gilead$467
  • Amarin Pharma, Inc.$161
  • AstraZeneca$134
  • AbbVie$127
  • Novartis$125
  • plus $387 from 4 others

What the payments were for

  • Food & beverage$2,87199%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,889 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$232,594
Medicare patients
249
Services billed
3,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin506$490,194
ProliaDenosumab72$120,397
JanuviaSitagliptin Phosphate82$66,886
EliquisApixaban64$54,267
Repatha SureclickEvolocumab73$48,379
VascepaIcosapent Ethyl60$34,956
VemlidyTenofovir Alafenamide16$28,285
OzempicSemaglutide26$22,784
EntrestoSacubitril/Valsartan28$22,069
FarxigaDapagliflozin Propanediol31$20,899
Praluent PenAlirocumab24$15,907
Atorvastatin Calcium1,059$14,040
Icosapent Ethyl25$9,461
Repatha PushtronexEvolocumab12$7,129
XareltoRivaroxaban11$7,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$1,489$120,39772 claims
GileadVemlidy$467$28,28516 claims
Novo NordiskOzempic$125$22,78426 claims
NovartisEntresto$125$22,06928 claims
AstraZenecaFarxiga$134$20,89931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Monterey Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →